Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

In April last year, the FDA’s Center for Veterinary Medicine released its GFI #256, “Compounding Animal Drugs from Bulk Drug Substances.” The GFI expresses the agency’s “current thinking” on the subject of compounding from bulk drug substances for animal health.

Maybe you knew this. But did you know that FDA plans to begin enforcement of the GFI on October 1, 2022? Compliance will mean that veterinary practices and compounding pharmacies will have to navigate through transformative changes in their policies, practices, and procedures.

We’re conducting a survey of compounding pharmacies to help APC understand your readiness for compliance with the GFI #256 – so that we can provide tools and training to support you in this transition and so that we can advise FDA about whether an enforcement delay is warranted.

Would you mind completing it? It should only take you about seven minutes.

Click here to take the survey. Deadline to complete it is Friday, August 26.